Neuland Laboratories Limited (NEULANDLAB) - Total Liabilities
Based on the latest financial reports, Neuland Laboratories Limited (NEULANDLAB) has total liabilities worth Rs10.56 Billion INR (≈ $114.17 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore NEULANDLAB long-term investment intensity to see how much of total assets are deployed in long-term investments.
Neuland Laboratories Limited - Total Liabilities Trend (2006–2026)
This chart illustrates how Neuland Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Neuland Laboratories Limited balance sheet assets.
Neuland Laboratories Limited Competitors by Total Liabilities
The table below lists competitors of Neuland Laboratories Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tongcheng Travel Holdings Ltd
F:TEM
|
Germany | €19.03 Billion |
|
Jiangsu Yangnong Chemical Co Ltd
SHG:600486
|
China | CN¥6.74 Billion |
|
Kadant Inc
NYSE:KAI
|
USA | $708.50 Million |
|
Hefei Chipmore Technology Co. Ltd. A
SHG:688352
|
China | CN¥2.14 Billion |
|
Hyundai Steel
KO:004020
|
Korea | ₩15.19 Trillion |
|
HSBC Holdings PLC
LSE:HSBA
|
UK | GBX3.24 Trillion |
|
Shanghai Xinmei Real Estate Co Ltd Class A
SHG:600732
|
China | CN¥28.84 Billion |
|
CVR Energy Inc
NYSE:CVI
|
USA | $3.33 Billion |
Liability Composition Analysis (2006–2026)
This chart breaks down Neuland Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Neuland Laboratories Limited to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neuland Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neuland Laboratories Limited (2006–2026)
The table below shows the annual total liabilities of Neuland Laboratories Limited from 2006 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs10.56 Billion ≈ $114.17 Million |
+61.15% |
| 2025-03-31 | Rs6.55 Billion ≈ $70.84 Million |
+19.14% |
| 2024-03-31 | Rs5.50 Billion ≈ $59.46 Million |
-6.11% |
| 2023-03-31 | Rs5.86 Billion ≈ $63.34 Million |
+7.86% |
| 2022-03-31 | Rs5.43 Billion ≈ $58.72 Million |
+0.87% |
| 2021-03-31 | Rs5.38 Billion ≈ $58.22 Million |
+3.32% |
| 2020-03-31 | Rs5.21 Billion ≈ $56.35 Million |
+20.87% |
| 2019-03-31 | Rs4.31 Billion ≈ $46.62 Million |
-16.03% |
| 2018-03-31 | Rs5.13 Billion ≈ $55.52 Million |
+51.00% |
| 2017-03-31 | Rs3.40 Billion ≈ $36.77 Million |
+0.76% |
| 2016-03-31 | Rs3.37 Billion ≈ $36.49 Million |
-3.57% |
| 2015-03-31 | Rs3.50 Billion ≈ $37.84 Million |
-2.60% |
| 2014-03-31 | Rs3.59 Billion ≈ $38.85 Million |
+10.59% |
| 2013-03-31 | Rs3.25 Billion ≈ $35.13 Million |
-7.03% |
| 2012-03-31 | Rs3.49 Billion ≈ $37.79 Million |
-0.74% |
| 2011-03-31 | Rs3.52 Billion ≈ $38.07 Million |
+6.93% |
| 2010-03-31 | Rs3.29 Billion ≈ $35.61 Million |
+10.57% |
| 2009-03-31 | Rs2.98 Billion ≈ $32.20 Million |
+33.75% |
| 2008-03-31 | Rs2.23 Billion ≈ $24.08 Million |
+59.28% |
| 2007-03-31 | Rs1.40 Billion ≈ $15.12 Million |
+47.24% |
| 2006-03-31 | Rs949.26 Million ≈ $10.27 Million |
-- |
About Neuland Laboratories Limited
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.